ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 387

Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis

Hyoungyoung Kim1, Yoon-Kyoung Sung2, Seongmi Choi3, Jinwook Kim4, Sun-Young Jung5, Eun Jin Jang6, Dae-Hyun Yoo7 and Soo-Kyung Cho1, 1Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 3Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), 4Department of Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), 5College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), 6Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), 7Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Elderly, inflammatory myositis, Malignancy and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The association between inflammatory myositis and malignancy is well established, however, the risk of malignancy in aged patients is known to be similar with general populations. We aimed to analyze the incidence of malignancy in elderly patients with inflammatory myositis, and to estimate the increased risk of malignancy of these patients compared to knee OA patients in Korea.

Methods: Patients with polymyositis (PM) and dermatomyositis (DM) over the age of 50 were identified from Korean nationwide claims database from January 2012 to December 2014 with excluding the patients who had history of any malignancy for a year prior to enrollment. They were observed until any malignancy was newly diagnosed or up to end of the study, December 2015. The crude incidence rate (IR) of malignancies in PM and DM patients over 50 years of age was estimated and we calculated age- and sex-adjusted standardized incidence ratio (SIR) by dividing the observed number of malignancies in patients with PM or DM by expected number of malignancies which was drawn from the incidence rate of malignancy in knee OA patients for cumulative person-years (PYs).

Results: A total of 683 patients with PM and 502 patients with DM over 50 years old were included. In PM patients, 46 cases of solid malignancy (217.7/10,000 PYs) and 4 of hematologic malignancy (18.2/10,000 PYs) occurred during 2,113 and 2,195 PYs of follow-up. On the other hand, the number of 36 solid malignancies (238.0/10,000 PYs) and 7 hematologic malignancies (44.7/10,000 PYs) were identified for 1,512 and 1,565 PYs of observation in patients with DM. Compared to patients with knee OA aged over 50 (n=5,476,302), the risk of overall malignancy was increased in both PM and DM patients; SIR was 1.4 (95% CI 1.0-1.8) in PM patients and 1.8 (95% CI 1.3-2.4) in DM patients, respectively. The risk of solid malignancy was also significantly increased than expected in patients with PM (SIR 1.4, 95% CI 1.0-1.8) and DM (SIR 1.6, 95% CI 1.1-2.1). However, the risk of hematologic malignancy was significantly increased in patients with DM (SIR 9.0, 95% CI 2.3-15.6), but not in those with PM (SIR 3.3, 95% CI 0.1-6.6).

Conclusion: We figure out that even in the elderly patients, inflammatory myositis is associated with increased risk of both solid and hematologic malignancies.


Disclosure: H. Kim, None; Y. K. Sung, None; S. Choi, None; J. Kim, None; S. Y. Jung, None; E. J. Jang, None; D. H. Yoo, None; S. K. Cho, None.

To cite this abstract in AMA style:

Kim H, Sung YK, Choi S, Kim J, Jung SY, Jang EJ, Yoo DH, Cho SK. Increased Risk of Malignancy in Elderly Patients with Inflammatory Myositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/increased-risk-of-malignancy-in-elderly-patients-with-inflammatory-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-risk-of-malignancy-in-elderly-patients-with-inflammatory-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology